[Experimental and clinical study of reduction surgery combined with chemotherapy of primary liver cancer].
The effects of reduction surgery combined with chemotherapy used by MMC and ADM for DAB induced hepatoma were investigated. Results are as follows. Reduction surgery prolonged the survival time of rats with DAB hepatoma in which tumor was transplanted either in liver or subcutaneous tissue. Reduction surgery in combination with chemotherapy made survival time more prolonged in these rats with than reduction surgery alone. Reduction surgery combined with intraarterial infusion chemotherapy was carried out in three patients with advanced primary liver cancer. One survived for 9 months and another for 3 years after right trisegmentectomy and postoperative arterial infusion chemotherapy. The other is till alive without any recurrence 7 months after right trisegmentectomy with partial resection of a intrahepatically metastasized tumor in the lateral segment and arterial infusion chemotherapy used by ADM. In summary, it is suggested that reduction surgery in combination with chemotherapy is beneficial as a multidisciplinary treatment for advanced primary liver cancer.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D006499:Hepatic Artery / Q000601:surgery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008099:Liver / Q000601:surgery; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009368:Neoplasm Transplantation; D051381:Rats
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin